Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.

Free
Posted in: Autologous, CAR-T, CD19 Jan 27 | 2023Breyanzi Meets Primary Endpoint in Pivotal Trial for R/R CLLAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Jan 27 | 2023Carvykti’s CARTITUDE-4 Met its Primary Endpoint in r/r MMAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Jan 27 | 2023Breyanzi 2L LBCL Absent from Third Consecutive Meeting; January’s CHMP HighlightsAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, Topics Jan 25 | 2023Carvykti’s Revenue Remains Flat; CARTITUDE-4 Readout Expected in 2023; JNJ Q4 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Jan 23 | 2023Breyanzi Absent from January’s CHMP AgendaAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T, TCR Jan 20 | 2023Thoughts on AstraZeneca's Cell Therapy PipelineAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19, CD22 Jan 13 | 2023JPM 2023 Analysis Day 4: Autolus and Caribou BiosciencesAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T Jan 12 | 2023JPM 2023 Analysis Day 3: Century Tx, Atara Bio, and PrecigenAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T, CD19, TCR Jan 11 | 2023Precision BioSciences and 2seventy bio Provide Business Updates for 2023; JPM 2023 Analysis Day 2: Allogene and GSKAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Jan 10 | 2023JPM 2023 Analysis Day 1: BMS, Novartis, JNJ, and GileadAccess Free Blast
Free
Posted in: Autologous, CAR-T Jan 10 | 2023Thoughts on Gilead’s Acquisition of TmunityAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T, CD19, TCR Jan 09 | 2023We're Back! Holiday Recap Ahead of JPM 2023Access Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD123, CD19 Dec 19 | 2022You May Have Missed: ASH 2022 AnalysesAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T Dec 16 | 2022Clinical Results from Autolus, Cellectis, and Precigen; ASH 2022 Analysis 7Access Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD123 Dec 16 | 2022Updated Results from CART-ddBCMA in R/R MM; Could Gilead Take an Interest in the ARC-SparX Platform? Arcellx Meets Clinical Milestones; ASH 2022 Arcellx Investor EventAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Dec 16 | 2022Breyanzi 2L LBCL Absent from December’s CHMP HighlightsAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Dec 15 | 2022Gilead, Novartis, and BMS Report Follow-up Data from Approved Lymphoma Therapies; ASH 2022 Analysis 6Access Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T, CD19 Dec 14 | 2022Novartis, CRISPR Tx, and Miltenyi Report Clinical Updates from Their New Assets in Lymphomas; ASH 2022 Analysis 5Access Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T Dec 14 | 2022BMS, Gracell, CARsgen, and Fate Tx Report Clinical Results from Next-Generation Assets in MM; ASH 2022 Analysis 4Access Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Dec 12 | 2022Updated Results from Breyanzi and Yescarta in 2L LBCL; ASH 2022 Analysis 3Access Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.